CSIMarket
 
Eiger Biopharmaceuticals Inc   (EIGR)
Other Ticker:  
 

Eiger Biopharmaceuticals Inc

Business Description


Eiger Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company located in Palo Alto, California. It was founded in 2008 with the aim of developing and commercializing innovative therapies for rare and ultra-rare diseases. The company*s primary focus is on the development of novel small-molecule drugs that target specific diseases with unmet medical needs.

Eiger Biopharmaceuticals is committed to addressing diseases that affect a small patient population and lack effective treatment options. The company employs a rigorous and comprehensive approach to drug development, utilizing scientific expertise, strategic partnerships, and a deep understanding of the underlying biology of diseases.

One of the key therapeutic areas of Eiger Biopharmaceuticals is in the field of Hepatitis Delta Virus (HDV) infection. HDV is considered the most severe form of viral hepatitis and affects approximately 15-20 million people worldwide. Eiger Biopharmaceuticals is dedicated to developing a potential first-in-class drug candidate, lonafarnib, for the treatment of HDV.

In addition to HDV, Eiger Biopharmaceuticals is actively researching and developing therapies for other rare diseases, including autoimmune diseases and metabolic disorders. The company has a pipeline of drug candidates in various stages of development, with promising results from preclinical and early-stage clinical studies.

Eiger Biopharmaceuticals has established strategic partnerships and collaborations with leading academic institutions, government agencies, and pharmaceutical companies to accelerate the development and commercialization of its therapies. They work closely with regulatory agencies to ensure compliance with strict safety and efficacy standards.

The company places great emphasis on patient-centeredness and prioritizes the needs of patients in its drug development efforts. Eiger Biopharmaceuticals actively engages with patient advocacy groups and aims to provide innovative and effective treatment options that can improve the lives of patients.

Overall, Eiger Biopharmaceuticals is a dedicated and innovative biopharmaceutical company that is driven by the mission to develop life-changing therapies for patients with rare and ultra-rare diseases. Through its rigorous research and development programs, strategic partnerships, and patient-centric approach, the company is committed to making a lasting impact on the field of biopharmaceuticals.



View Company Supplier View Company Competition View Company Customers


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com